Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDA Review Pilot Will Be Mandatory, Assuming Program Flies At All

Executive Summary

The proposed review model for new molecular entity new drug applications and original biologics license applications remains under discussion along with several other Prescription Drug User Fee Act reauthorization issues.
Advertisement

Related Content

PDUFA V: Review Model Evaluators Will Observe All FDA-Sponsor Meetings
PDUFA V Agreement Appears Set Between FDA And Industry
PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue
PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue
PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue
FDA Could Answer "Clarifying" Questions, But Only For Firms Without Approved Product
FDA Could Answer "Clarifying" Questions, But Only For Firms Without Approved Product
FDA May Require NDA Pre-Filing Meeting Under PDUFA V Review Model; Pilot Launching Soon
User Fee Inflation Calculations May Need To Change Due To Slow Economic Recovery

Topics

Advertisement
UsernamePublicRestriction

Register

PS053187

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel